Budesonide

證據等級: L5

預測適應症: 10 個

Budesonide: From Asthma & Inflammatory Airway Disease to Atopic Eczema

One-Sentence Summary

Budesonide is a potent synthetic glucocorticosteroid with well-established global use in asthma, allergic rhinitis, and inflammatory bowel disease, though it currently holds no regulatory registration in Singapore. The TxGNN model predicts it may be effective for Atopic Eczema (prediction score 99.96%), with 2 clinical trials and 20 publications identified in the evidence search. The majority of evidence remains preclinical or observational (Evidence Level L3), placing this prediction at the "Research Question" stage — dedicated translational studies with topical budesonide formulations are needed before clinical consideration.

Quick Overview

Item	Content
Original Indication	No Singapore registration (globally: asthma, allergic rhinitis, Crohn's disease)
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.96%
Evidence Level	L3
Singapore Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Budesonide is a synthetic glucocorticosteroid that acts through the glucocorticoid receptor (GR) to suppress inflammatory pathways. Although formal mechanism of action data is absent from the Singapore regulatory database, the scientific literature indicates that budesonide inhibits Th2-mediated immune responses — specifically suppressing IL-4, IL-13, and TSLP signalling — while also reducing mast cell activation and pro-inflammatory cytokine transcription. These are precisely the pathways central to the pathogenesis of atopic eczema, a chronic Th2-driven inflammatory skin condition characterised by epidermal barrier dysfunction and persistent pruritus.

Topical corticosteroids are already the first-line pharmacological treatment for atopic eczema in global clinical practice, which makes the TxGNN prediction biologically coherent. The more specific proposition here involves using budesonide in novel topical formulations — for instance, a 2024 study (PMID 38275852) engineered budesonide-loaded pH-sensitive polymeric nanoparticles in a hydrogel matrix, specifically designed to exploit the acidic microenvironment of atopic lesions to improve dermal drug deposition while reducing systemic absorption. This represents a concrete and innovative translational pathway.

However, a critical nuance must be acknowledged: budesonide is itself documented as a contact allergen in patients with atopic dermatitis, as confirmed in multiple patch-test studies including data from Asian dermatology centres. This paradoxical safety signal — where the treatment candidate may sensitise the target patient population — must be prospectively evaluated and cannot be dismissed at the research question stage.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01028560	Phase 1/2	Completed	58	Allergy immunotherapy study in atopic, wheezing children aged 18 months to 3 years at high risk for persistent asthma. Budesonide is likely used as background standard-of-care rather than as the primary intervention; primary endpoint is asthma prevention, not atopic eczema skin outcomes. Indirect relevance only.
NCT04680117	N/A (Observational)	Unknown	150	Observational endotype characterisation study of severe paediatric asthma combining phenotypic, immune, metabolomic, and microbiota analyses in children aged 0–12 years. Atopy (including eczema) is a descriptive feature of recruited patients but there is no budesonide intervention arm and no dermatological outcome endpoint.

Note: Both identified trials carry a Grade C relevance rating. No direct Phase 2 or 3 RCTs evaluating budesonide as a primary treatment specifically for atopic eczema were identified in this evidence search.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38275852	2024	Formulation / Preclinical	Gels	Budesonide-loaded Eudragit L 100 nanoparticles formulated into pH-sensitive hydrogels for local therapy of paediatric atopic dermatitis; demonstrates improved dermal deposition and sustained release exploiting the acidic pH of atopic lesions
21062310	2010	RCT (Veterinary)	J Vet Pharmacol Ther	Randomised, blinded, placebo-controlled crossover trial (n=29 dogs) of budesonide 0.025% leave-on conditioner (Barazone) in canine atopic dermatitis; significant reductions in skin lesion scores, pruritus, and improved quality of life
8864369	1996	Clinical Study	Dermatology	Examined IGF axis, bone turnover, and collagen markers in children with atopic dermatitis treated with topical glucocorticosteroids including budesonide; quantified systemic absorption and growth-suppressive risk of percutaneous corticosteroid exposure
19875223	2010	RCT (Secondary Analysis)	Allergologia et Immunopathologia	Evaluated differential budesonide response in atopic vs non-atopic infants and preschoolers with recurrent wheezing; atopic phenotype modifies treatment response — relevant to patient selection
35133669	2022	Observational / Cohort	Contact Dermatitis	Contact sensitisation patterns in AD patients at an Asian dermatology centre; budesonide identified as a positive patch-test allergen in this population — direct safety signal for dermal application in the target indication
24603519	2014	Observational	Dermatitis	Contact hypersensitivity to corticosteroid series including budesonide in adolescents and adults with atopic dermatitis; rate of sensitisation documented even in the AD population historically assumed to be immunologically suppressed
40020933	2025	Translational / Basic Science	J Allergy Clin Immunol	Cutaneous ceramide synthesis dysregulation in paediatric eosinophilic esophagitis mirrors the barrier dysfunction of atopic dermatitis; provides mechanistic context linking budesonide's established mucosal anti-inflammatory efficacy to shared epithelial pathophysiology
31705907	2020	Review	J Allergy Clin Immunol	Reviews emerging therapies for eosinophilic esophagitis; swallowed topical corticosteroids including budesonide represent the current standard off-label treatment, confirming budesonide's mucosal anti-inflammatory potency across epithelial surfaces
16925687	2006	Clinical Study	Pediatric Allergy Immunol	Exhaled breath condensate pH in atopic children with asthma, allergic rhinitis, and atopic dermatitis; establishes atopic dermatitis as a component of the atopic march and a co-phenotype relevant to corticosteroid treatment planning
14616123	2003	Clinical Study	Allergy	Frequency of corticosteroid allergy — including budesonide — investigated in asthma patients; delayed contact allergy documented, with budesonide serving as the European Baseline Series marker for Group B corticosteroid hypersensitivity

Singapore Market Information

Budesonide currently holds no regulatory registration with the Health Sciences Authority (HSA) of Singapore. No product authorisation records are available.

Budesonide is a long-established medicine available internationally under brand names such as Pulmicort (inhaled suspension/dry powder), Rhinocort (nasal spray), Entocort / Budenofalk (oral capsules for Crohn's disease), and Jorveza (orodispersible tablet for eosinophilic esophagitis, approved in Europe). Any therapeutic use in Singapore — including a new dermatological indication — would require a full new drug application or regulatory submission to HSA.

Safety Considerations

Please refer to the package insert for safety information.

Signal from evidence review: Multiple publications in this evidence search identified budesonide as a documented contact allergen in patients with atopic dermatitis (PMID 35133669, PMID 24603519, PMID 14616123). This represents a paradoxical safety concern: the target patient population carries a non-trivial risk of contact hypersensitivity to budesonide itself. Budesonide is the standard patch-test marker for Group B corticosteroid allergy in the European Baseline Series. Mandatory patch testing before topical application should be incorporated into any future clinical protocol for this indication.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction is mechanistically coherent — Th2 suppression via GR is the established mechanism for atopic eczema treatment — but the evidence base for budesonide specifically in this indication remains limited to preclinical formulation work and indirect observational data. No direct human RCT of budesonide as a dedicated topical treatment for atopic eczema has been identified. The paradoxical risk of budesonide contact sensitisation in this very patient population adds a further safety hurdle requiring prospective evaluation before clinical advancement.

To proceed, the following is needed:

Patch test safety screening protocol to identify budesonide-sensitised individuals before any topical exposure in the atopic eczema population
Phase 1/2 human clinical trial of the budesonide nanoparticle hydrogel formulation (PMID 38275852) with dermal pharmacokinetics and safety as primary endpoints
Comparative efficacy study against established topical corticosteroids already available globally (e.g., mometasone furoate, betamethasone valerate) to define the therapeutic niche for budesonide
Regulatory pre-submission consultation with HSA Singapore, given the complete absence of any budesonide registration in Singapore
Formal MOA data retrieval from DrugBank API (Data Gap DG002) to support mechanistic sections of any HSA submission

Secondary note: Among all 10 predicted indications in this report, bronchitis (rank 2) carries a stronger evidence base (Level L2, "Proceed with Guardrails") supported by two completed Phase 2 RCTs of inhaled budesonide/formoterol in bronchiolitis obliterans (NCT00624754, NCT01560689). If resource prioritisation is required, the bronchitis indication offers a more immediately actionable pathway and should be evaluated in parallel.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.